Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142,321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Yan H, Song L, Li Y, Xu Q, Guo W, Lin S, Jiang W, Wang Z, Deng L, Huang Z, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Yu J, Dong X, Gong Q, Deng J, Chen X, Wang J, Zhang G, Yang N, Zhang Y, Zeng L. Yan H, et al. Among authors: chen x. Cancer Immunol Immunother. 2024 Mar 7;73(4):74. doi: 10.1007/s00262-024-03660-2. Cancer Immunol Immunother. 2024. PMID: 38451314 Free PMC article.
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
Huang Z, Zhang Y, Xu Q, Song L, Li Y, Guo W, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Yu J, Dong X, Gong Q, Deng J, Chen X, Wang J, Zhang G, Yang N, Zeng L, Zhang Y. Huang Z, et al. Among authors: chen x. Lung Cancer. 2024 Jun;192:107827. doi: 10.1016/j.lungcan.2024.107827. Epub 2024 May 21. Lung Cancer. 2024. PMID: 38795459
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial.
Zeng L, Yan H, Jiang W, Qin H, Dai J, Zhang Y, Wei S, Chen S, Liu L, Xiong Y, Yang H, Li Y, Wang Z, Deng L, Xu Q, Peng L, Zhang R, Fang C, Chen X, Deng J, Wang J, Li T, Liu H, Zhang G, Yang N, Zhang Y. Zeng L, et al. Among authors: chen s, chen x. Med. 2025 Jun 13;6(6):100574. doi: 10.1016/j.medj.2025.100574. Epub 2025 Jan 31. Med. 2025. PMID: 39892382 Clinical Trial.
Potential utility of albumin-bilirubin and body mass index-based logistic model to predict survival outcome in non-small cell lung cancer with liver metastasis treated with immune checkpoint inhibitors.
Song L, Xu Q, Zhong T, Guo W, Lin S, Jiang W, Wang Z, Deng L, Huang Z, Qin H, Yan H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Dong X, Li T, Fang C, Chen X, Deng J, Wang J, Yang N, Zeng L, Zhang Y. Song L, et al. Among authors: chen x. Chin Med J (Engl). 2025 Feb 20;138(4):478-480. doi: 10.1097/CM9.0000000000003385. Epub 2025 Feb 19. Chin Med J (Engl). 2025. PMID: 39967297 Free PMC article. No abstract available.
NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancer.
Ma L, Zhang X, Xu S, Dai J, Huang Z, Ruan Z, Zhang Y, Zhou X, Sun Y, Chen Y, Yan H, Zou C, Xiang SQ, Li J, Chen Y, Xu T, Zhang R, Yang D, Tian F, Zou N, Liao Y, Zou J, Jiang W, Chen X, Zhang J, Deng J, Xiang H, Zeng L, Zhang Y. Ma L, et al. Among authors: chen x, chen y. Lung Cancer. 2025 Dec;210:108841. doi: 10.1016/j.lungcan.2025.108841. Epub 2025 Nov 12. Lung Cancer. 2025. PMID: 41242286
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
Zeng L, Ruan Z, Yan H, Qin H, Zeng Z, Zou C, Huang Z, Jiang W, Dai J, Xu S, Song L, Chen Y, Zhang Y, Zeng F, Wei S, Chen S, Liu L, Xiong Y, Wang Z, Deng J, Zhang X, Sun Y, Yang D, Zhou C, Yang H, Li Y, Deng L, Xu Q, Fang C, Chen X, Wang J, Li T, Zhang G, Zhou H, Yang N, Zhang Y. Zeng L, et al. Among authors: chen s, chen x, chen y. Nat Commun. 2025 Dec 15;17(1):567. doi: 10.1038/s41467-025-67262-x. Nat Commun. 2025. PMID: 41398162 Free PMC article. Clinical Trial.
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, Xiong Y, Zhou C, Yang H, Liu L, Dai J, Zou N, Xu S, Wang Y, Wang Z, Deng J, Chen X, Wang J, Xiang H, Li X, Duchemann B, Chen G, Xia Y, Mok T, Scheiermann C, Lévi F, Yang N, Zhang Y. Huang Z, et al. Among authors: chen g, chen x. Nat Med. 2026 Apr;32(4):1233-1240. doi: 10.1038/s41591-025-04181-w. Epub 2026 Feb 2. Nat Med. 2026. PMID: 41629425 Clinical Trial.
142,321 results
You have reached the last available page of results. Please see the User Guide for more information.